Patent · US Active

Pertussis antigens and use thereof in vaccination

US8574596B2 · kind B2 · utility

9Cited by

3References

13Claims

0Family size

Assignee

GLAXOSMITHKLINE BIOLOGICALS SA · BE

Inventors

Cindy Castado · Rixensart, BE
Philippe Denoel · Rixensart, BE
Fabrice Godfroid · Rixensart, BE
Jan Poolman · Broek in Waterland, NL

Key dates

Filing date	Oct 1, 2004
Grant date	Nov 5, 2013
Priority date	—
Expiry date	Jul 15, 2027

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides BASB232 polypeptides and polynucleotides encoding BASB232 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. The invention further provides immunogenic compositions comprising a plurality of antigens selected from at least two different categories of antigen, having different functions within Bordetella. Examples of such categories of antigen are autotransporter proteins, iron acquisition proteins, lipoproteins, adhesins and toxins/invasins.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.